Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein

Biochimica et Biophysica Acta - Biomembranes

Volumn 1778, Issue 10, 2008, Pages 2127-2137

  Gordon, Larry M ^a   Nisthal, Alex ^b   Lee, Andy B ^b   Eskandari, Sepehr ^b   Ruchala, Piotr ^c   Jung, Chun Ling ^c   Waring, Alan J ^a,c   Mobley, Patrick W ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aggregation; AIDS; Congo red; Electron microscopy; Fibrils; Fourier transform infrared; Hemolysis; Light scattering; Prion; Surface plasmon resonance

Indexed keywords

ALANINE; AMINO TERMINAL TELOPEPTIDE; AMYLOID BETA PROTEIN; GLYCINE; GLYCOPROTEIN GP41; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ARTICLE; CORRELATION ANALYSIS; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; STRUCTURAL HOMOLOGY;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; COLORING AGENTS; CONGO RED; ERYTHROCYTES; HEMOLYSIS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 52049108928     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2008.05.002     Document Type: Article

References (84)

1. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., and Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4 (1998) 1302-1307
2. Jiang S., Zhao Q., and Debnath A.K. Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des. 8 (2002) 563-580
3. 13C-enhanced Fourier transform infrared spectroscopy. Biochim. Biophys. Acta 1559 (2002) 96-120
4. + lymphocytes. Biochim. Biophys. Acta 1139 (1992) 251-256
5. Dimitrov A.S., Xiao X., Dimitrov D.S., and Blumenthal R. Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J. Biol. Chem. 276 (2001) 30335-30341
6. Pillot T., Drouet B., Queille S., Labeur C., Vandekerckhove J., Rosseneu M., Pincon-Raymond M., and Chambaz J. The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. J. Neurochem. 73 (1999) 1626-1634
7. Mobley P.W., Pilpa R., Brown C., Waring A.J., and Gordon L.M. Membrane-perturbing domains of HIV Type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses 17 (2001) 311-327
8. Mobley P.W., Barry J.A., Waring A.J., Sherman M.A., and Gordon L.M. Membrane perturbing actions of HIV Type 1 glycoprotein 41 domains are inhibited by helical C-peptides. AIDS Res. Hum. Retroviruses 23 (2007) 224-242
9. Munch J., Standker L., Andermann K., Schulz A., Schindler M., Chinnadurai R., Pohlmann S., Chaipan C., Biet T., Peters T., Meyer B., Wilhelm D., Lu H., Jing W., Jiang S., Forssmann W.-G., and Kirchhoff F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129 (2007) 263-275
10. Mobley P.W., Waring A.J., Sherman M.A., and Gordon L.M. Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs. Biochim. Biophys. Acta 1418 (1999) 1-18
11. Mobley P.W., Lee H.-F., Curtain C.C., Kirkpatrick A., Waring A.J., and Gordon L.M. The amino-terminal peptide of HIV-1 glycoprotein 41 fuses human erythrocytes. Biochim. Biophys. Acta 1271 (1995) 304-315
12. Chang D.-K., Cheng S.-F., and Chien W.-J. The amino-terminal fusion domain peptide of Human Immunodeficiency Virus Type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as a helix with a conserved glycine at the micelle-water interface. J. Virol. 71 (1997) 6593-6602
13. Morris K.F., Gao X., and Wong T.C. The interactions of HIV gp41 fusion peptides with zwitterionic membrane mimics determined by NMR spectroscopy. Biochim. Biophys. Acta 1667 (2004) 67-81
14. 13C-enhanced Fourier transform infrared spectroscopy. Protein Sci. 13 (2004) 1012-1030
15. Jaroniec C.P., Kaufman J.D., Stahl S.J., Viard M., Blumenthal R., Wingfield P.T., and Bax A. Structure and dynamics of micelle-associated Human Immunodeficiency Virus gp41 fusion domain. Biochemistry 44 (2005) 16167-16180
16. Li Y., and Tamm L.K. Structure and plasticity of the Human Immunodeficiency Virus gp41 fusion domain in lipid micelles and bilayers. Biophys. J. 93 (2007) 876-885
17. Yang J., Gabrys C.M., and Weliky D.P. Solid-state nuclear magnetic resonance evidence for an extended β strand conformation of the membrane-bound HIV-1 fusion peptide. Biochemistry 40 (2001) 8126-8137
18. Kanyalkar M., Srivastava S., Saran A., and Coutinho E. Conformational study of fragments of envelope proteins (gp120: 254-274 and gp41: 519-541) of HIV-1 by NMR and MD simulations. J. Pept. Sci. 10 (2004) 363-380
19. 13C FTIR study. J. Mol. Biol. 350 (2005) 790-805
20. Qiang W., Yang J., and Weliky D.P. Solid-state nuclear magnetic resonance measurements of HIV fusion peptide to lipid distances reveal the intimate contact of beta strand peptide with membranes and the proximity of the Ala-14-Gly-16 region with lipid headgroups. Biochemistry 46 (2007) 4997-5008
21. Callebaut I., Tasso A., Brasseur R., Burny A., Portetelle D., and Mornon J.P. Common prevalence of alanine and glycine in mobile reactive centre loops of serpins and viral fusion peptides: do prions possess a fusion peptide?. J. Comput. Aided Mol. Des. 8 (1994) 175-191
22. Tamm L.K., and Han X. Viral fusion peptides: a tool set to disrupt and connect biological membranes. Biosci. Rep. 20 (2000) 501-518
23. Saez-Cirion A., Nieva J.L., and Gallaher W.R. The hydrophobic internal region of bovine prion protein shares structural and functional properties with HIV type 1 fusion peptide. AIDS Res. Hum. Retroviruses 19 (2003) 969-978
24. Slepushkin V.A., Andreev S.M., Sidorova M.V., Melikyan G.B., Grigoriev V.B., Chumakov V.M., Grinfeldt A.E., Manukyan R.A., and Karamov E.V. Investigation of human immunodeficiency virus fusion peptides. Analysis of interrelations between their structure and function. AIDS Res. Hum. Retroviruses 8 (1992) 9-18
25. Pereira F.B., Goni F.M., and Nieva J.L. Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: dose and sequence effects. Biophys. J. 73 (1997) 1977-1986
26. Pillot T., Lins L., Goethals M., Vanloo B., Baert J., Vandekerckhove J., Rosseneu M., and Brasseur R. The 118-135 peptide of the human prion protein forms amyloid fibrils and induces liposome fusion. J. Mol. Biol. 274 (1997) 381-393
27. Yang J., and Weliky D.P. Solid-state Nuclear Magnetic Resonance evidence for parallel and antiparallel strand arrangements in the membrane-associated HIV-1 fusion peptide. Biochemistry 42 (2003) 11879-11890
28. Serpell L.C. Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502 (2000) 16-30
29. Sticht H., Bayer P., Willbold D., Dames S., Hilbich C., Beyreuther K., Frank R.W., and Rosch P. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 233 (1995) 293-298
30. Coles M., Bicknell W., Watson A.A., Fairlie D.P., and Craik D.J. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?. Biochemistry 37 (1998) 11064-11077
31. Crescenzi O., Tomaselli S., Guerrini R., Salvadori S., D'Ursi A.M., Temussi P.A., and Picone D. Solution structure of the Alzheimer amyloid β-peptide (1-42) in an apolar microenvironment. Similarity with a viral fusion domain. Eur. J. Biochem. 269 (2002) 5642-5648
32. de Planque M.R., Raussens V., Contera S.A., Rijkers D.T., Liskamp R.M., Ruysschaert J.-M., Ryan J.F., Separovic F., and Watts A. Beta-sheet structured beta-amyloid(1-40) perturbs phosphatidylcholine model membranes. J. Mol. Biol. 368 (2007) 982-997
33. Barrow C.J., and Zagorski M.G. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 253 (1991) 179-182
34. Fraser P.E., Nguyen J.T., Inouye H., Surewicz W.K., Selkoe D.J., Podlisny M.B., and Kirschner D.A. Fibril formation by primate, rodent and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry 31 (1992) 10716-10723
35. Petkova A.T., Ishii Y., Balbach J.J., Antzutkin O.N., Leapman R.D., Delaglio F., and Tycko R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16742-16747
36. Trovato A., Seno F., and Tosatto S.C.E. The PASTA server for protein aggregation prediction. Protein Eng. Des. Sel. 20 (2007) 521-523
37. Trovato A., Chiti F., Maritan A., and Seno F. Insight into the structure of amyloid fibrils from the analysis of globular proteins. PloS Comput. Biol. 2 (2006) e170
38. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12243-12247
39. Jayakumar R., Kusiak J.W., Chrest F.J., Demehin A.A., Murali J., Wersto R.P., Nagababu E., Ravi L., and Rifkind J.M. Red cell perturbations by amyloid beta-protein. Biochim. Biophys. Acta 1622 (2003) 20-28
40. Mattson M.P., Begley J.G., Mark R.J., and Furukawa K. Abeta25-35 induces rapid lysis of red blood cells: contrast with Aβ1-42 and examination of underlying mechanisms. Brain Res. 771 (1997) 147-153
41. Thompson M.J., Sievers S.A., Karanicolas J., Ivanova M.I., Baker D., and Eisenberg D. The 3D profile method for identifying fibril-forming segments of proteins. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 4074-4078
42. Halverson K., Fraser P.E., Kirschner D.A., and Lansbury Jr. P.T. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic β-protein fragments. Biochemistry 29 (1990) 2639-2644
43. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4967
44. Halverson K.J., Sucholeiki I., Ashburn T.T., and Lansbury Jr. P.T. Location of beta-sheet-forming sequences in amyloid proteins by FTIR. J. Am. Chem. Soc. 113 (1991) 6701-6703
45. Hughes E., Burke R.M., and Doig A.J. Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J. Biol. Chem. 275 (2000) 25109-25115
46. Del Mar Martinez-Senac M., Villalain J., and Gomez-Fernandez J.C. Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem. 265 (1999) 744-753
47. Pillot T., Goethals M., Vanloo B., Talussot C., Brasseur R., Vandekerckhove J., Rosseneu M., and Lins L. Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide. J. Biol. Chem. 271 (1996) 28757-28765
48. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of Amyloid Beta protein: reversal by tachykinin neuropeptides. Science 250 (1990) 279-282
49. Demeester N., Baier G., Enzinger C., Goethals M., Vandekerckhove J., Rosseneu M., and Labeur C. Apoptosis induced in neuronal cells by C-terminal amyloid beta-fragments is correlated with their aggregation properties in phospholipid membranes. Mol. Membr. Biol. 17 (2000) 219-228
50. 25-32-induced lysis more effectively than ApoE. NeuroReport 13 (2002) 2149-2154
51. Westermark P., Benson M.D., Buxbaum J.N., Cohen A.S., Frangione B., Ikeda S., Masters C.L., Merlini G., Saraiva M.J., and Sipe J.D. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12 (2005) 1-4
52. Westermark P. Aspects of human amyloid forms and their fibril polypeptides. FEBS J. 272 (2005) 5942-5949
53. Buxbaum J.N. Diseases of protein conformation: what do in vitro experiments tells us about in vivo diseases?. TIBS 28 (2003) 585-592
54. Gordon L.M., Waring A.J., Curtain C.C., Kirkpatrick A., Leung C., Faull K., and Mobley P.W. Antivirals that target the amino-terminal domain of HIV-1 gp41. AIDS Res. Hum. Retroviruses 11 (1995) 677-686
55. Gordon L.M., Curtain C.C., Zhong Y.C., Kirkpatrick A., Mobley P.W., and Waring A.J. The amino terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: peptide conformation, orientation and aggregation. Biochim. Biophys. Acta 1139 (1992) 257-274
56. Gordon L.M., Curtain C.C., McCloyn V., Kirkpatrick A., Mobley P.W., and Waring A.J. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin. AIDS Res. Hum. Retroviruses 9 (1993) 1145-1156
57. Walther F.J., Waring A.J., Hernandez-Juviel J., Gordon L.M., Schwan A.L., Jung C.-L., Chang Y., Wang Z., and Notter R.H. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS ONE 2 (2007) e1039
58. Kawatake S., Nishimura Y., Sakaguchi S., Iwaki T., and Doh-ura K. Surface plasmon resonance analysis for the screening of anti-prion compounds. Biol. Pharm. Bull. 29 (2006) 927-932
59. Nichols M.R., Moss M.A., Reed D.K., Cratic-McDaniel S., Hoh J.H., and Rosenberry T.L. Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J. Biol. Chem. 280 (2005) 2471-2480
60. Trovato A., Maritan A., and Seno F. Aggregation of natively folded proteins: a theoretical approach. J. Phys. Condens. Matter 19 (2007) 285221
61. Waring A.J., Harwig S.S.L., and Lehrer R.I. Structure and activity of protegrin-1 in model lipid membranes. Protein Pept. Lett. 3 (1996) 177-184
62. 2-terminal HIV-1 gp41 peptide in fused and aggregated liposomes. Biochim. Biophys. Acta 1145 (1993) 124-133
63. Byler D.M., and Susi H. Examination of the secondary structure of protein by deconvolved FTIR spectra. Biopolymers 25 (1986) 469-487
64. Agirre A., Flach C., Goni F.M., Mendelsohn R., Valpuesta J.M., Wu F., and Nieva J.L. Interactions of the HIV-1 fusion peptide with large unilamellar vesicles and monolayers. A cryo-TEM and spectroscopic study. Biochim. Biophys. Acta 1467 (2000) 153-164
65. Surewicz W.K., and Mantsch H.H. New insight into protein secondary structure from resolution-enhanced infrared spectra. Biochim. Biophys. Acta 952 (1988) 115-130
66. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., and Beyreuther K. Aggregation and secondary structure of synthetic Amyloid BetaA4 peptides of Alzheimer's disease. J. Mol. Biol. 218 (1991) 149-163
67. Kohno T., Kobayashi K., Maeda T., Sato K., and Takashima A. Three-dimensional structures of the amyloid β peptide (25-35) in membrane-mimicking environment. Biochemistry 35 (1996) 16094-16104
68. D'Ursi A.M., Armenante M.R., Guerrini R., Salvadori S., Sorrentino G., and Picone D. Solution structure of amyloid beta-peptide (25-35) in different media. J. Med. Chem. 47 (2004) 4231-4238
69. Zandomeneghi G., Krebs M.R.H., McCammon M.G., and Fandrich M. FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Sci. 13 (2004) 3314-3321
70. Nettleton E.J., Tito P., Sunde M., Bouchard M., Dobson C.M., and Robinson C.V. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys. J. 79 (2000) 1053-1065
71. Bouchard M., Zurdo J., Nettleton E.J., Dobson C.M., and Robinson C.V. Formation of insulin amyloid fibrils followed by FTIR simultaneous with CD and electron microscopy. Protein Sci. 9 (2000) 1960-1967
72. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272 (1997) 22364-22372
73. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274 (1999) 25945-25952
74. Wojtowicz W.M., Farzan M., Joyal J.L., Carter K., Babcock G.J., Israel D.I., Sodroski J., and Mirzabekov T. Stimulation of enveloped virus infection by beta-amyloid fibrils. J. Biol. Chem. 277 (2002) 35019-35024
75. Mingeot-Leclercq M.P., Lins L., Bensliman M., Van Bambeke F., Van Der Smissen P., Peuvot J., Schanck A., and Brasseur R. Membrane destabilization induced by Beta-amyloid peptide 29-42: importance of the amino terminus. Chem. Phys. Lipids 120 (2002) 57-74
76. Westermark G.T., Johnson K.H., and Westermark P. Staining methods for identification of amyloid in tissue. Meth. Enzymol. 309 (1999) 3-25
77. Caughey B., Ernst D., and Race R.E. Congo red inhibition of scrapie agent replication. J. Virol. 67 (1993) 6270-6272
78. Touil F., Pratt S., Mutter R., and Chen B. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance. J. Pharm. Biomed. Anal. 40 (2006) 822-832
79. Maezawa I., Hong H.-S., Liu R., Wu C.-Y., Cheng R.H., Kung M.-P., Kung H.F., Lam K.S., Oddo S., Laferla F.M., and Jin L.-W. Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem. 104 (2008) 457-468
80. Cairo C.W., Strzelec A., Murphy R.M., and Kiessling L.L. Affinity-based inhibition of beta-amyloid toxicity. Biochemistry 41 (2002) 8620-8629
81. Avdulov N.A., Chochina S.V., Igbavboa U., O'Hare E.O., Schroeder F., Cleary J.P., and Wood W.G. Amyloid β-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J. Neurochem. 68 (1997) 2086-2091
82. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Amyloid pores from pathogenic mutations. Nature 418 (2002) 291
83. Aloia R.C., Jensen F.C., Curtain C.C., Mobley P.W., and Gordon L.M. Lipid composition and fluidity of the human immunodeficiency virus type-1. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 900-904
84. Aloia R.C., Tian H., and Jensen F.C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 5181-5185